About CELCUITY INC.
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway. The company's lead product candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTORC1/2 inhibitor.
Developing targeted therapies for multiple solid tumor indicationsAdvancing a robust pipeline of therapies focused on the PI3K/AKT/mTOR pathwayPotent inhibition of all four Class I PI3K isoforms and mTORC1/2 at low nanomolar concentrations
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CELCUITY INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.